These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21955611)

  • 1. The interaction between fluvastatin and warfarin.
    Wang HT; Chen YL
    Int J Cardiol; 2012 Feb; 155(1):167-8. PubMed ID: 21955611
    [No Abstract]   [Full Text] [Related]  

  • 2. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.
    Harv Heart Lett; 2007 Dec; 18(4):1-2. PubMed ID: 18219801
    [No Abstract]   [Full Text] [Related]  

  • 4. The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children.
    Biss TT; Avery PJ; Williams MD; Brandão LR; Grainger JD; Kamali F
    J Thromb Haemost; 2013 Feb; 11(2):373-5. PubMed ID: 23279643
    [No Abstract]   [Full Text] [Related]  

  • 5. [Anticoagulation with warfarin].
    Schinzel H; Nitschmann S
    Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract]   [Full Text] [Related]  

  • 6. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 7. Using genetic testing to guide warfarin therapy.
    Ungerer LL; Pestka EL; Messner PK
    Nursing; 2012 May; 42(5):63-5. PubMed ID: 22531080
    [No Abstract]   [Full Text] [Related]  

  • 8. Anticoagulant therapy: warfarin sensitivity genotyping closer to clinical practice.
    van der Zee SA; Halperin JL
    Nat Rev Cardiol; 2010 Oct; 7(10):549-50. PubMed ID: 20865027
    [No Abstract]   [Full Text] [Related]  

  • 9. Dynamic pharmacogenetic models in anticoagulation therapy.
    Bon Homme M; Reynolds KK; Valdes R; Linder MW
    Clin Lab Med; 2008 Dec; 28(4):539-52. PubMed ID: 19059061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refining the use of warfarin through genetic testing.
    Lee SC
    Int Angiol; 2008 Aug; 27(4):271-3. PubMed ID: 18677287
    [No Abstract]   [Full Text] [Related]  

  • 11. Warfarin anticoagulation in children: is there a role for a personalized approach to dosing?
    Biss TT; Kamali F
    Pharmacogenomics; 2012 Aug; 13(11):1211-4. PubMed ID: 22920389
    [No Abstract]   [Full Text] [Related]  

  • 12. Pathology consultation on warfarin pharmacogenetic testing.
    Stack G;
    Am J Clin Pathol; 2011 Jan; 135(1):13-9. PubMed ID: 21173120
    [No Abstract]   [Full Text] [Related]  

  • 13. Genotype and adverse drug reactions to warfarin.
    Byron KA; Dear AE
    Med J Aust; 2007 Jul; 187(1):61-2. PubMed ID: 17605718
    [No Abstract]   [Full Text] [Related]  

  • 14. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.
    Mannucci PM; Spreafico M; Peyvandi F
    J Thromb Haemost; 2008 Sep; 6(9):1450-2. PubMed ID: 18627441
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacogenomic testing for warfarin dosing: we are ready now.
    Wu AH
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1483-5. PubMed ID: 19954308
    [No Abstract]   [Full Text] [Related]  

  • 16. Warfarin and pharmacogenomic testing: what would Pascal do?
    Teagarden JR
    Pharmacotherapy; 2009 Mar; 29(3):245-7. PubMed ID: 19249943
    [No Abstract]   [Full Text] [Related]  

  • 17. Algorithms using clinical and genetic data (CYP2C9, VKORC1) are relevant to predict warfarin dose in patients with different INR targets.
    Le Cam-Duchez V; Frétigny M; Cailleux N; Gandelin C; Lévesque H; Borg JY
    Thromb Res; 2010 Sep; 126(3):e235-7. PubMed ID: 20569971
    [No Abstract]   [Full Text] [Related]  

  • 18. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
    Wen MS; Lee M; Chen JJ; Chuang HP; Lu LS; Chen CH; Lee TH; Kuo CT; Sun FM; Chang YJ; Kuan PL; Chen YF; Charng MJ; Ray CY; Wu JY; Chen YT
    Clin Pharmacol Ther; 2008 Jul; 84(1):83-9. PubMed ID: 18183038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using pharmacogenetics in real time to guide warfarin initiation: a clinician update.
    Carlquist JF; Anderson JL
    Circulation; 2011 Dec; 124(23):2554-9. PubMed ID: 22144632
    [No Abstract]   [Full Text] [Related]  

  • 20. The long and winding road to warfarin pharmacogenetic testing.
    Ginsburg GS; Voora D
    J Am Coll Cardiol; 2010 Jun; 55(25):2813-5. PubMed ID: 20579536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.